MX2023009620A - Metodos terapeuticos. - Google Patents
Metodos terapeuticos.Info
- Publication number
- MX2023009620A MX2023009620A MX2023009620A MX2023009620A MX2023009620A MX 2023009620 A MX2023009620 A MX 2023009620A MX 2023009620 A MX2023009620 A MX 2023009620A MX 2023009620 A MX2023009620 A MX 2023009620A MX 2023009620 A MX2023009620 A MX 2023009620A
- Authority
- MX
- Mexico
- Prior art keywords
- therapeutic methods
- present disclosure
- inclusive
- administering
- dose
- Prior art date
Links
- 238000002560 therapeutic procedure Methods 0.000 title 1
- 208000007536 Thrombosis Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
- A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/727—Heparin; Heparan
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
La presente descripción se refiere a un método para el tratamiento o la prevención de un trastorno trombótico, que comprende administrar a un sujeto que lo necesita una cantidad eficaz del Compuesto (1), o una sal farmacéuticamente aceptable de este, en una dosis en el intervalo de 0.01-0.3 mg/kg, inclusive. La presente descripción se refiere, además, a composiciones para su uso en dicho método.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202163150301P | 2021-02-17 | 2021-02-17 | |
PCT/US2022/016571 WO2022177968A1 (en) | 2021-02-17 | 2022-02-16 | Therapeutic methods |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2023009620A true MX2023009620A (es) | 2023-11-01 |
Family
ID=82931154
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2023009620A MX2023009620A (es) | 2021-02-17 | 2022-02-16 | Metodos terapeuticos. |
Country Status (9)
Country | Link |
---|---|
EP (1) | EP4294402A1 (es) |
JP (1) | JP2024507294A (es) |
KR (1) | KR20230157354A (es) |
CN (1) | CN117098538A (es) |
AU (1) | AU2022224562A1 (es) |
BR (1) | BR112023016459A2 (es) |
CA (1) | CA3211215A1 (es) |
MX (1) | MX2023009620A (es) |
WO (1) | WO2022177968A1 (es) |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104936598B (zh) * | 2012-01-16 | 2017-11-03 | 洛克菲勒大学 | 化合物、药物组合物及其用途 |
EP3810134A4 (en) * | 2018-06-19 | 2022-03-30 | Celecor Therapeutics, Inc. | DEUTERED RUC-4 |
-
2022
- 2022-02-16 CA CA3211215A patent/CA3211215A1/en active Pending
- 2022-02-16 AU AU2022224562A patent/AU2022224562A1/en active Pending
- 2022-02-16 BR BR112023016459A patent/BR112023016459A2/pt unknown
- 2022-02-16 JP JP2023574302A patent/JP2024507294A/ja active Pending
- 2022-02-16 MX MX2023009620A patent/MX2023009620A/es unknown
- 2022-02-16 WO PCT/US2022/016571 patent/WO2022177968A1/en active Application Filing
- 2022-02-16 EP EP22756821.9A patent/EP4294402A1/en active Pending
- 2022-02-16 CN CN202280025886.8A patent/CN117098538A/zh active Pending
- 2022-02-16 KR KR1020237031649A patent/KR20230157354A/ko unknown
Also Published As
Publication number | Publication date |
---|---|
EP4294402A1 (en) | 2023-12-27 |
KR20230157354A (ko) | 2023-11-16 |
CA3211215A1 (en) | 2022-08-25 |
CN117098538A (zh) | 2023-11-21 |
AU2022224562A1 (en) | 2023-08-31 |
WO2022177968A1 (en) | 2022-08-25 |
JP2024507294A (ja) | 2024-02-16 |
BR112023016459A2 (pt) | 2023-10-10 |
WO2022177968A8 (en) | 2022-11-17 |
WO2022177968A9 (en) | 2022-10-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CR20210563A (es) | Compuestos y métodos para el tratamiento de covid-19 | |
MX2018003331A (es) | Administracion de potenciadores de regulador de la conductancia transmembrana de fibrosis quistica (cftr) deuterados. | |
MX2021005651A (es) | Combinacion farmaceutica para el tratamiento contra el cancer. | |
TW200639159A (en) | Treatment of pain | |
MX2021015854A (es) | Composiciones y métodos para tratar trastornos del snc. | |
CR20230052A (es) | Combinaciones para el tratamiento de cáncer. | |
MY150682A (en) | Method for using vasopressin antagonist with anthracycline chemotherapy agents to reduce cardiotoxicity and/or improve survival | |
WO2020033838A3 (en) | Treatment of egfr-mutant cancer | |
MX2022015629A (es) | Uso de vibegron para tratar vejiga sobreactiva. | |
MX2022003845A (es) | Tratamientos cognitivos medicinales. | |
PH12019500618A1 (en) | Pharmaceutical composition and method for treatment of non-alcoholic fatty liver disease | |
CA2595363A1 (en) | Methods and materials with trans-clomiphene for the treatment of male infertility | |
MX2024004846A (es) | Compuesto tetraciclico que contiene nitrogeno, metodo de preparacion del mismo y uso medico del mismo. | |
MX2023013225A (es) | Inhibidores de la cinasa 4 similar a polo. | |
MX2023003332A (es) | Inhibidores del elemento 1 interdispersado largo (line-1) para el tratamiento de enfermedades. | |
MX2024002409A (es) | Terapias contra el cancer. | |
PH12020551117A1 (en) | Compositions for preventing or treating uveitis | |
MX2023011203A (es) | Derivado de cumarina para terapia o profilaxis de un trastorno proliferativo celular. | |
MX2023009620A (es) | Metodos terapeuticos. | |
MX2020007817A (es) | Prevención y tratamiento del trastorno del sueño. | |
MX2022005029A (es) | Metodos de tratamiento y/o prevencion de acontecimientos cardiovasculares adversos graves (mace) con una combinacion de un inhibidor de bromodominio y extraterminal (bet) y un inhibidor de transporte de glucosa dependiente de sodio 2. | |
MX2023004435A (es) | Compuestos y composiciones para el tratamiento de la criptosporidiosis. | |
MX2023004516A (es) | Uso de pridopidina y analogos para el tratamiento de la ansiedad y la depresion. | |
PH12020551620A1 (en) | Compositions for preventing or treating dry eye | |
MX2021015390A (es) | Tratamiento para sinucleinopatias. |